BioSpace News Archive

Tenax Therapeutics, Inc. (Nasdaq: TENX), a specialty pharmaceutical company focused on identifying, developing and commercializing products that address cardiovascular and pulmonary diseases with high unmet medical need, announced today that the United States Patent and Trademark Office (USPTO) has allowed its patent application with claims covering the use of TNX-103 (oral levosimendan).

Enzymedica is pleased to announce the appointment of Michael Graham as the Vice President of Operations.

A Stony Brook University team of researchers led by Gábor Balázsi , PhD, has identified DNA amplification as a major cause of drug resistance in engineered mammalian cell lines and has identified a novel approach to overcome it in those cells as well as in two human cancer cell lines.

Complete Genomics, a California-based life sciences company that provides novel, comprehensive sequencing solutions, highlighted expanded sequencing applications enabled by DNBSEQ™-T7, a leading high- throughput sequencer which will be the subject of customer talks at the Advances in Genome Biology and Technology General Meeting.

Intrommune Therapeutics, Inc. today announced data from The First Study To Evaluate Oral Mucosal Immunotherapy (OMIT) For The Treatment Of Food Allergy has been selected as a Late Breaking Poster Presentation at the 2024 American Academy of Allergy, Asthma & Immunology in Washington, DC.

Therma Bright Inc. (TSXV: THRM) (OTCQB: TBRIF) (“Therma” or the “Company”), developer and partner in a wide-range of leading-edge, proprietary diagnostic and medical device technologies

Upsher-Smith Laboratories, LLC and the National Alliance of State Pharmacy Associations proudly announce the recipients of the 2023 NASPA Excellence in Innovation Award.

New methods enable deep coverage of the blood and tissue proteome, expand capabilities for dynamic biomarker discovery to include metabolites, lipids, and proteins

Almac Group today announced a 15-year virtual power purchase agreement (VPPA) with renewable energy provider

Cardinal Health announced that its Board of Directors approved a quarterly dividend of $0.5006 per share out of the Company’s capital surplus.